Mide Kanseri’nde Erken Tanı Hayat Kurtarır

Mide kanseri, dünyada en sık görülen 5 kanserden biridir. Görülme sıklığı dünya genelinde büyük coğrafi farklılıklar göstermektedir. Mide Kanseri Japonya’da kanserden ölümlerin başlıca nedenlerindendir, bu ülkede erken tanı için endoskopideki gelişmelerle birlikte ulusal tarama programları uygulanarak mide kanserine erken tanı konmaya başlanmıştır. Mide kanseri sebepleri arasında: Helikobakter pilori, atrofik gastrit, intestinal metaplazi ve displazi, aşırı tuzlu gıda ile beslenme ve genetik yatkınlık gösterilmektedir. Mide kanserlerinin %90’dan fazlası adenokanser tipinde olup genellikle tanı anında ileri evrededir. 5 yıllık yaşam bu grupta %15-20’dir. Erken mide kanserinde endoskopik olarak submukozal rezeksiyon yapılarak kür sağlanabilmektedir. Eğer evre 2 ve üzeri mide kanseri ise geç kabul edilmektedir. Geç mide kanserinde hastalığın durumuna göre cerrahi rezeksiyon, kemoterapi veya radyoterapi yapılabilmektedir.

Anahtar Kelimeler:

mide, mide kanseri, evreleme, erken evre

Early Diagnosis in Stomach Cancer Saves Lives

Stomach cancer is one of the 5 most common cancers in the world. Its incidence varies widely across the world. Stomach Cancer is one of the main causes of cancer deaths in Japan, with the developments in endoscopy for early diagnosis in this country, early diagnosis of gastric cancer has been started by applying national screening programs. Among the causes of stomach cancer: Helicobacter pylori, atrophic gastritis, intestinal metaplasia and dysplasia, eating with high-salt food and genetic predisposition. More than 90% of stomach cancers are of the adenocarcinoma type and are usually advanced at the time of diagnosis. 5-year life is 15-20% in this group. Early gastric cancer can be cured by endoscopic submucosal resection. If it is stage 2 and above stomach cancer, it is considered late. In late stomach cancer, surgical resection, chemotherapy or radiotherapy can be performed depending on the condition of the disease.

Keywords:

stomach, gastric cancer, staging, early stage,

PDF

___

1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globacan 2012. Int J Cancer 2015;136:359-86
2.Şenateş E, İnce AT, Erken mide kanseri. Güncel gastroenteroloji;2011:161-165.
3.Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37 Suppl 8:4-66.
4. Hirschowitz BI. Endoscopy--40 years since fiber optics. Any light at the end of the tunnel?. Dig Surg. 2000;17(2):115-117.
5. Hisamichi S, Sugawara N. Mass screening for gastric cancer by X-ray examination. Jpn J Clin Oncol. 1984;14(2):211-223.
6. Shiratori Y, Nakagawa S, Kikuchi A, et al. Significance of a gastric mass screening survey. Am J Gastroenterol. 1985;80(11):831-834.
7. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 2001;48(2):225-229.
8.Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer. 1998;1(1):10-24.
9. Lauren p. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
10. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38-v49. doi:10.1093/annonc/mdw350
11. Nakamura K, Sugano H, Takagi K, Kumakura K. Gan No Rinsho. 1969;15(7):627-647.
12. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet. 1975;2(7924):58-60.
13. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203(2):681-687.
14. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol. 2015;16(2):60-70.
15. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361-374.
16. Stjepanovic N, Moreira L, Carneiro F, et al. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(10):1558-1571.
17. Yoshida N, Doyama H,Yano T., et al. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging Gut 2020;0:1-9. doi:10.1136/gutjnl-2019-319631